Articles From: - Chipotle Cultivate Foundation Awards $500,000 Grant to the International Rescue Committee to 2014/11/16 - Alibaba and the truth behind the Singles Day sales numbers

The Chipotle Cultivate Foundation has renewed its support for the International Rescue Committee (IRC) New Roots Program with a two-year, $500,000 grant to help finance expansion of the program’s MicroProducer Academy.
Sign-up for - Chipotle Cultivate Foundation Awards $500,000 Grant to the International Rescue Committee investment picks PALM CITY, FL--(Marketwired - November 17, 2014) - GelStat Corporation (PINKSHEETS: GSAC) ( News ), a fully integrated consumer healthcare company engaged in the development, marketing, branding and manufacturing of innovative over-the-counter (OTC) consumer healthcare products, reports third quarter results and releases a shareholder update.
Sign-up for - GelStat Corporation Reports Third Quarter Results and Releases a Shareholder Update investment picks
Fortune 1000 companies reported an estimated $285 billion in retiree medical obligations for 2013, according to calculations based on required Securities and Exchange Commission financial disclosures as of December 31, 2013.
Sign-up for 2014/11/17 - Fortune 1000 Companies Have a $285 Billion Liability for Retiree Medical investment picks
Company to Provide Geospatial Solutions RESTON, Va.
Sign-up for - Leidos Awarded Contract by National Geospatial-Intelligence Agency investment picks
FXCM Inc. (NYSE:FXCM) today announces that Chief Financial Officer Robert Lande is scheduled to speak at the Keefe Bruyette & Woods Securities Brokerage & Market Structure Conference being held November 19, 2014 in New York.
Sign-up for - FXCM to Speak at the Keefe Bruyette & Woods Securities Brokerage & Market Structure Conference investment picks
GRAPEVINE, Texas , Nov.
Sign-up for - United Development Funding IV Announces Special Distribution investment picks
By Tomi Kilgore, MarketWatch U.S.-listed stock declines aren't quite as dramatic as the Nikkei 225's selloff NEW YORK (MarketWatch) -- Reports that Japan slipped into a recession during the third quarter spilled over into the U.S. stock market, as shares of Japanese companies listed in the U.S., and those of U.S. companies with significant exposure to Japan, traded broadly lower on Monday.
Sign-up for 2014/11/17 - Japan's recession hits U.S.-traded stocks investment picks ABERDEEN, SCOTLAND --
Sign-up for - Ithaca Energy Inc. Director Shareholding investment picks NICOSIA, CYPRUS --
Sign-up for - EMED Mining Public Limited ("EMED" or the "Company") Update Regarding EGM Requisition Notice investment picks
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, this week recognizes the 10 th anniversary of its unique Equinoxe ® Shoulder System .
Sign-up for - Industry’s Fastest Growing Shoulder System Marks 10 Years of Improving Patient Outcomes investment picks
Karisma Hotels & Resorts is pleased to announce a landmark partnership with Viacom International Media Networks (VIMN) a division of Viacom Inc. (NASDAQ:VIAB and VIA) to bring Nickelodeon brand experiences to Azul Hotels by Karisma.
Sign-up for - Karisma Hotels & Resorts Partners with Viacom International Media Networks to Debut Exclusive Nickelodeon Experiences at Azul Hotels by Karisma investment picks
Sign-up for - Brixmor Property Group Completes Secondary Offering investment picks
Meritage Homes Corporation (NYSE: MTH), a leading U.S. homebuilder, announced today that Meritage management will be speaking to investors at the Southwest IDEAS Investor Conference on November 20, 2014 at the Marriott – Quorum Hotel in Addison, Texas.
Sign-up for - Meritage Homes to Present at the Southwest IDEAS Investor Conference on November 20th in Dallas investment picks
Glancy Binkow & Goldberg LLP is investigating potential claims against the Board of Directors of ChyronHego Corp.
Sign-up for - Glancy Binkow & Goldberg LLP is Investigating ChyronHego Corp. Board of Directors investment picks
AUSTIN, Texas , Nov.
Sign-up for - Hanger Postpones Release of Third Quarter 2014 Financial Results investment picks
By Mark Hulbert, MarketWatch Money managers tend to make major changes around the beginning of the year CHAPEL HILL, N.C. (MarketWatch) -- Don't sell any of your large-cap stocks, and don't buy any small-caps.
Sign-up for 2014/11/16 - UPDATE: Why you should favor large-cap stocks for the next six weeks investment picks
-Only Rentrak Provides the Official Global Movie Results- LOS ANGELES , Nov.
Sign-up for - Rentrak Announces Official Worldwide Box Office Results for Weekend of November 16, 2014 investment picks
Botox maker Allergan Inc. (AGN) and Irish pharmaceutical company Actavis PLC (ACT) are close to a friendly deal, which could be announced as early as Monday, the Wall Street Journal reported Sunday.
Sign-up for - Allergan, Actavis near cash-and-stock deal: WSJ investment picks
The Medicines Company (NASDAQ:MDCO) today presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated.
Sign-up for - The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients investment picks
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol.
Sign-up for - AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting investment picks
Months of dedication and hard work in science, technology, engineering and mathematics (STEM) paid off tonight for three students named National Finalists in the Siemens Competition in Math, Science & Technology, the nation’s premier research competition for high school students.
Sign-up for - Arizona and New Mexico High School Scientists Win Regional Siemens Competition at the University of Texas at Austin for Research on Intrinsically Disordered Proteins for Drug Discovery and Computational Models of Tree Growth investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trading in Monday's session are Tyson Foods Inc., Urban Outfitters Inc. and Agilent Technologies Inc. Tyson Foods (TSN) is projected to post fiscal fourth-quarter earnings of 76 cents a share, according to a consensus survey by FactSet.
Sign-up for - UPDATE: Tyson, Urban Outfitters, Agilent earnings in focus investment picks
By Wallace Witkowski, MarketWatch Home Depot, Lowe's, Target report results SAN FRANCISCO (MarketWatch) -- Earnings season wraps up this week as the last Dow component and most of the remaining S&P 500 companies report.
Sign-up for 2014/11/16 - UPDATE: Retailers close out earnings season investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months.
Sign-up for - Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced preliminary results from a phase 1 investigator-sponsored trial (IST) evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma.
Sign-up for - Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -066, a Phase 3 randomized double blind study, comparing Opdivo , an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma (n=418). The study met the primary endpoint of overall survival (OS) with the median OS not reached for Opdivo vs.
Sign-up for - Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial investment picks
By Daniel Gilbert HOUSTON --
Sign-up for 2014/11/16 - Investigators to probe DuPont's deadly Texas chemical leak investment picks
By Qu Yunxu BEIJING (Caixin Online) -- Alibaba Group Holding Ltd.'s (BABA) annual e-commerce frenzy smashed last year's record, but company executives were not exactly ecstatic.
Sign-up for 2014/11/16 - Alibaba and the truth behind the Singles Day sales numbers investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.


Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: - Chipotle Cultivate Foundation Awards $500,000 Grant to the International Rescue Committee to 2014/11/16 - Alibaba and the truth behind the Singles Day sales numbers
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent